Molecular Genetic Lesions and Clinical Outcome in Pediatric ALL Patients
- Examine the prognostic significance of deletion of the p16 (MTS1, CDKN21) gene in
children with acute lymphoblastic leukemia.
- Attempt to correlate the incidence of specific, nonrandom combinations of molecular
genetic lesions with clinical outcome in these patients.
OUTLINE: Patients are stratified by risk (standard vs high).
Bone marrow specimens from patients enrolled in CCG-1922, CCG-1882, or CCG-1901 are analyzed
for the following genetic lesions: p16 deletion, p14 deletion, and p15 deletion.
Patients do not receive the results of the genetic testing and the results do not influence
the type or duration of treatment.
Patients are followed for at least 3 years.
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
Primary Purpose: Diagnostic
Ursula R. Kees, PhD
Telethon Institute for Child Health Research
United States: Federal Government